Sun Pharma and Christian Siriano launch alopecia areata education campaign
The 'Regrowth Restyled' campaign pairs a fashion designer with patients to spotlight hair regrowth, shifting focus from loss to recovery.
Medicine & Biotech
Clinical AI, drug discovery, devices, and regulatory approvals.
RFK Jr. Defends Vaccine Skepticism at His Former Group's Conference
The HHS secretary appeared before the anti-vaccine nonprofit he helped create and renewed his criticism of vaccines, with one outlet noting the backdrop of a Pennsylvania measles outbreak.
Lisata and Marea merge to advance cardio and endocrine drugs
The all-stock merger pairs Lisata's oncology focus with Marea's mid-stage cardiovascular and endocrine pipeline, backed by $225 million in financing.
Rare EGFR Variant Tied to 25-Fold Lung Cancer Risk in Never-Smokers
Two reports describe a rare inherited EGFR mutation that may help explain why some people who never smoked develop lung cancer.
All 50 States Join Medicaid Drug Pricing Model, Trump Announces
The president says every state will participate in a Medicaid program aimed at lowering drug prices, but key details remain unclear.
Electra Therapeutics raises $350M in upsized IPO
The inflammation biotech's listing adds to a wave of large biotech IPOs not seen since 2021.
Xenon halts phase 3 depression trials after psychosis reports
The voluntary pause raises safety questions about azetukalner just as the FDA reviews the same drug for epilepsy.
Novo CEO Doustdar Stays Bullish, Prioritizes Heritage in Rebrand
Novo's new CEO signals continuity over upheaval as the company rebrands after losing GLP-1 ground to Eli Lilly.
Legend Biotech names Novartis veteran Ingrid Zhang as permanent CEO
The CAR-T cell therapy maker has filled its top job with a 15-year Novartis executive as it pushes to expand commercial reach.
New U.S. China Investment Rules Likely to Spare Most Pharma Licensing Deals
Both Fierce Pharma and STAT report that draft U.S. Treasury rules will probably preserve most licensing deals for Chinese-developed drugs, easing a major industry worry.
North Immunology Goes Public via Reverse Merger to Advance Eczema Drug
The inflammation biotech is taking a bispecific antibody for atopic dermatitis public through a $180M reverse merger with Aethlon Medical.
Novo bets $1.4B on oral macrocycles, adds three obesity drugs from Kallyope
Two new deals show Novo's push to replenish its cardiometabolic pipeline with early-stage oral therapies.
Roche and Dualitas team up to screen 300,000 bispecific combos
A deal worth up to $1 billion will let Roche tap Dualitas' high-throughput screening platform for new immunology and inflammation therapies.
Novartis Pays $125M for Sironax Blood-Brain Barrier Platform
The deal gives Novartis a way to move large-molecule drugs into the central nervous system, at a time when its neuroscience pipeline has suffered setbacks.
Gilead's CEO says oncology and inflammation push has reached 'critical mass'
Gilead's CEO says the company's diversification into oncology and inflammation has reached a critical mass after a series of acquisitions.
FDA approves Ultragenyx gene therapy Fayuvi for Sanfilippo syndrome type A
The first treatment for the underlying cause of Sanfilippo syndrome type A wins approval, marking Ultragenyx's second gene therapy.